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Strengths and limitations of this study
 ► This is the first study to evaluate the efficacy and 
cost-effectiveness of ankle (talocrural) osteoarthritis 
(OA) in a multicentre, stratified, block-randomised, 
double-blind, placebo-controlled trial design. A pos-
itive study outcome will have a significant effect on 
widespread availability and nationwide implementa-
tion of an intra-articular injection treatment for ankle 
OA with platelet-rich plasma (PRP). A negative out-
come (no effect of PRP), will prevent the widespread 
use of a non-efficacious treatment on patients.
 ► The study population consists only of patients with 
isolated ankle OA and no concomitant OA in other 
major joints of the lower extremities that negatively 
affects their daily activity level.
 ► The PRP used in this randomised controlled trial 
is an available PRP product that is used in clinical 
practice.
 ► There is a multitude of commercial PRP products 
available that differ in their production method and 
content, and different treatment regimens regarding 
dose, timing and number of injections are used in 
clinical practice. The generalisability to other PRP 
products and treatment regimens remains unknown.
 ► The composition of PRP will not be analysed; this 
decision was based on the fact that PRP preparation 
and composition has frequently been analysed and 
is typically not performed in clinical practice prior 
to injection.
AbStrACt
Introduction Platelet-rich plasma (PRP) is a potentially 
efficacious treatment for ankle osteoarthritis (OA), but 
its use has not been examined in high-quality studies. 
Systematic reviews show that PRP injections significantly 
decrease pain and improve function in patients with knee 
OA. Ankle OA is more common than hip or knee OA in the 
young active population; with a prevalence of 3.4%.
PRP injections in ankle OA are shown to be safe and 
improve quality of life over time, but no randomised 
controlled trial has been conducted. Our randomised 
controlled trial will evaluate the efficacy of PRP injections 
for symptom reduction and functional improvement, 
compared with placebo, in the treatment of ankle 
(talocrural) OA.
Methods and analysis We will conduct the Platelet-
Rich plasma Injection Management for Ankle OA study: 
a multicentre, randomised, placebo-controlled trial. 
One hundred patients suffering from ankle OA will be 
randomised into two treatment groups: PRP injection 
or placebo (saline) injection. Both groups will receive 
two injections of PRP or placebo at an interval of 6 
weeks. Primary outcome is the American Orthopaedic 
Foot and Ankle Society score at 26 weeks. Secondary 
outcomes determined at several follow-up moments up 
to 5 years, include Ankle Osteoarthritis Score, Foot and 
Ankle Outcome Score, pain subscale of (0–40), Visual 
Analogue Scale score (0–100), Ankle Activity Score 
(0–10), subjective patient satisfaction Short Form Health 
Survey-36, Global Attainment Scaling and the EuroQol-5 
dimensions-3 levels utility score. A cost-effectiveness 
analysis will be performed at 1 year.
Ethics and dissemination The study is approved by the 
Medical Ethics Review Committee Amsterdam Medical 
Center, the Netherlands (ABR 2018–042, approved 
23 July 2018) and registered in the Netherlands trial 
register (NTR7261). Results and new knowledge will be 
disseminated through the Dutch Arthritis Association 
(ReumaNederland), Dutch patient federation, conferences 
and published in a scientific peer-reviewed journal.
trial registration number NTR7261.
bACkground And rAtIonAlE
Platelet-rich plasma (PRP) is a potentially 
efficacious treatment for ankle osteoar-
thritis (OA), but its use has not been exam-
ined in high-quality studies. Ankle OA is 
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more common than hip or knee OA in the young active 
population.1 The incidence of symptomatic ankle OA is 
estimated to be 3.4% in the general adult population.1 
Patients with ankle OA have a quality of life and physical 
functioning comparable with hip OA, end-stage kidney 
disease or congestive heart failure.2 These relatively young 
(predominantly female) patients have an increased risk 
for decreased work participation and family care. The 
available surgical intervention (arthrodesis) is associated 
with significant functional limitations. In contrast to hip 
and knee OA, where joint replacement is an excellent 
surgical alternative for severe cases, there is a clear need 
for effective non-surgical interventions in ankle OA.
PRP is defined as plasma containing a concentration of 
at least 1 000 000 platelets/μL.3 Growth factors are stored 
in α-granules within platelets, and are released in a selec-
tive manner on activation. Growth factors released from 
the α-granules of platelets are assumed to provide the 
regenerative benefits of PRP.
Recent reviews concluded that in animal models 
PRP can diminish multiple inflammatory interleukin 
(IL)-1-mediated effects.4 Due to this local anti-inflam-
matory response, PRP might have an indirect analgesic 
effect. The second suggested effect might be protection 
of the cartilage from destructive pro-inflammatory ILs. 
This is mediated due to an increased messenger RNA 
expression of proteoglycan core protein in the articular 
cartilage and decreased chondrocyte apoptosis.4 Conse-
quently, PRP could positively influence the collagen 
network of the cartilage.
Recent systematic reviews on the intra-articular injec-
tion therapy in ankle OA found a lack of evidence from 
high-quality studies to assist in clinical decision-making.5 6 
When compared with placebo injections, hyaluronic acid 
or corticosteroid injections, PRP injections might signifi-
cantly decrease pain and improve function in patients 
with knee OA.7–9 Given the clinical effect on pain reduc-
tion in knee OA and a good safety profile, PRP is a prom-
ising non-surgical therapy for ankle OA.10 11 PRP might 
delay the irreversible surgical options like arthrodesis. 
No significant adverse events have been reported in any 
PRP trials regarding ankle OA, knee OA, acute hamstring 
injuries or Achilles tendinopathy.8 12–17 Clinical studies on 
PRP in ankle OA are limited to a single report of 5 cases 
and a prospective case series of 20 subjects, which both 
showed safety and significant reduction of pain at a mean 
of 16 months and 12 weeks follow-up.14 18 Well-designed 
prospective randomised controlled trials (RCT) have not 
yet been performed.
MEthodS And dESIgn
objectives
We aim to determine the efficacy of PRP injections in the 
management of ankle OA by comparing two groups, both 
receiving two injections of either PRP or placebo solu-
tion. We hypothesise that PRP injections are efficacious 
for symptom reduction and functional improvement 
compared with placebo in the treatment of ankle 
(talocrural) OA.
Study design
The Platelet-Rich plasma Injection Management for 
Ankle OA (PRIMA) study is a multicentre, stratified, 
block‐randomised, double‐blind, placebo‐controlled 
trial design will be conducted in order to compare two 
treatment groups: PRP versus placebo (saline). After the 
26 weeks follow-up of the last patient in the study, the 
principal investigator and coordinating researcher will be 
unblinded only after the analysis of the primary outcome. 
A flow chart of the design and follow-up is shown in 
figure 1. The study included its first patient in August 
2018 and aims to include the last patient by January 2021, 
consequently allowing analysis and then deblinding to 
commence after the last follow-up (26 weeks) of the last 
patient by July 2021.
Patient involvement
Active patient involvement through reviewing the proposal 
(reviewer level)
Active involvement of patients during the design phase 
was performed by two patients with ankle OA. Both 
reviewed the grant proposal and provided feedback.
Execution phase: patients will actively contribute
Active patient involvement will be secured by invitation of 
at least two patients for the annual trial monitoring and 
evaluation meetings (informant level).
Analysis phase: patient will review and interpret the results 
(reviewer level)
Using the blinded codes of the randomisation groups 
and after breaking the randomisation code, patients (also 
active in the design phase) will be given the opportunity 
to interpret the results from a patient perspective.
Dissemination phase: patient-oriented approach (advisor level)
Results and new knowledge will be disseminated through 
the Dutch Arthritis Association (ReumaNederland), the 
Dutch patient federation, conferences and published in a 
scientific peer-reviewed journal. Dissemination activities 
will comprise a social media strategy with active patient 
involvement to share results with online patient commu-
nities and an events attendance strategy enabling patient 
participation in seminars, conferences and workshops.
Study population
Population (base)
Patients with ankle OA in University Medical Centres, 
teaching hospitals, general hospitals and private specialist 
clinics will be informed about the study. In order to 
participate, patients must meet the eligibility criteria 
documented below.
Inclusion criteria
1. Severity of ankle OA pain on a Visual Analogue Scale 
(VAS 0–100 mm) ≥40 mm during daily activities
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Figure 1 Illustrating the Platelet-Rich plasma Injection 
Management for Ankle OA multicentre randomised controlled 
trial design and follow-up procedure. AOFAS, American 
Orthopaedic Foot and Ankle Society; OA, osteoarthritis.
2. X-rays (anteroposterior (AP) and lateral view) indicat-
ing ≥grade 2 talocrural OA on the van Dijk classifica-
tion (clarified under the ‘Radiographs’ section).19
3. Age≥18 years.
Exclusion criteria
1. Patient has received injection therapy for ankle OA in 
the previous 6 months.
2. Patient does not want to receive one of the two thera-
pies.
3. Patient has clinical signs of concomitant OA of one or 
more other major joints of the lower extremities that 
negatively affects their daily activity level.
4. Previous ankle surgery for OA or osteochondral de-
fects <1 year (not including surgery for an ankle frac-
ture in the past).
radiographs
AP and lateral X-rays of the talocrural joints will be scored 
according to the van Dijk classification19:
1. Normal joint or subchondral sclerosis.
2. Osteophytes without joint space narrowing.
3. Joint space narrowing with or without osteophytes.
4. (Sub)total disappearance or deformation of the joint 
space.
randomisation, blinding and treatment allocation
We will include patients at the centre of their first outpa-
tient clinic appointment. For each patient the coordi-
nating researcher will prepare a syringe with PRP and a 
syringe with placebo (isotonic saline: 0.9% sodium chlo-
ride). A Good Clinical Practice (GCP) approved data 
management system (Castor EDC, based in Amsterdam, 
the Netherlands) will be used to perform a computer-gen-
erated block randomisation scheme with patients strati-
fied to centre with a variable block size of 2, 4 or 6. This 
procedure will ensure treatment allocation concealment. 
The coordinating researcher, treating physician and 
patient all remain blinded to the allocated intervention. 
An independent researcher from the coordinating loca-
tion will have access to the randomisation result and the 
allocated intervention. This will be relayed to a GCP-cer-
tified research assistant at the centre. The research 
assistant then selects one of the two syringes based on 
the allocated intervention and blinds the syringe with a 
covering sheath, ensuring concealment of the content of 
the syringe. The patients, treating physicians and coor-
dinating researcher will all be blinded to the allocation 
of the intervention and to the contents of the syringe. 
The success of blinding will be assessed by asking patients 
which injection they think they have received just after 
the injection procedure, this will then be registered 
accordingly.
After the 26 weeks follow-up of the last patient in 
the study, the principal investigator and coordinating 
researcher will be unblinded only after the analysis of the 
primary outcome. The patients will remain blinded to the 
therapy until the 52 weeks follow-up (online supplemen-
tary appendix 1) of the last patient in the study.
Intervention
In this study, patients will be randomised into two treat-
ment groups: PRP injection or placebo saline injec-
tion. For each patient, the coordinating researcher will 
prepare a PRP and a placebo injection (isotonic saline: 
0.9% sodium chloride). The PRP syringe will be prepared 
according to the instructions of the manufacturer.12 
Prior to commencement of the study, the coordinating 
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researcher was trained by a representative of Arthrex, 
as well as two experienced members of the PRIMA trial 
research group (GR and RJdV) with a vast scientific expe-
rience regarding PRP preparation and injection.12 13 The 
PRP will be prepared using a widely used and commer-
cially available system (Arthrex double syringe PRP 
system, Arthrex Medizinische Instrumente GmbH, 
Garching, Germany).
One syringe of 15 mL autologous blood will be 
collected twice from the cubital vein: at inclusion and 
at a time interval of 6 weeks. After blood collection the 
syringe will undergo 5 min of centrifugation and the 
injection will be given within 30 min following venepunc-
ture to prevent formation of blood clots. No additional 
substances (calcium, thrombin or citrate) will be added 
to the PRP solution. For each procedure, 2 mL of PRP or 
placebo will be prepared and injected into the affected 
ankle joint under ultrasonographic guidance using a 
sterile technique. All patients will receive a second injec-
tion at 6 weeks, regardless of the effect of the first injec-
tion. To guarantee blinding for the allocated treatment 
of the patient, treatment assessor and treating physician, 
blood will be drawn and both PRP and placebo will be 
prepared according to exactly the same procedure for 
each patient (both at inclusion and at a time interval of 
6 weeks after the first injection). However, in the control 
group, patients will be injected with 2 mL of physiolog-
ical saline instead of PRP. An unblinded research assis-
tant will blind one of the two identical syringes based 
on the allocated intervention using a specially manufac-
tured covering sheath in order to conceal randomisation. 
Following the intra-articular injection, the syringe covered 
by the sheath (containing either the remnants of the PRP 
or saline) is handed to the unblinded research assistant, 
who will dispose of the syringe, therefore keeping the 
treating physician and coordinating researcher blinded. 
After the intervention, patients are advised to avoid heavy 
or repetitive stress to the ankle joint for a period of 48 
hours. Furthermore, patients receive a leaflet containing 
usual-care healthy lifestyle advice beneficial for ankle OA. 
This includes losing weight and exercise (avoiding heavy 
or repetitive ankle loading exercises) such as walking, 
cycling or swimming.
use of co-intervention
Patients are instructed to avoid the use of co-interventions 
and non-steroidal anti-inflammatory drugs if possible, 24 
hours prior to the intervention and if possible up to a year 
after the first injection. Throughout the study, key treat-
ment (including usual care: exercise therapy and healthy 
lifestyle advice) and co-interventions used by patients will 
be registered, such as non-steroidal anti-inflammatory 
drugs, other analgesic drugs, intra-articular injections or 
inlays.
Study procedures
In the event the patient meets the criteria for inclusion 
and exclusion, the patient will be informed in more detail 
about the study procedure. At that time, the patient can 
ask questions about the study and decide whether they 
will participate and sign the informed consent form. 
Subsequently, the patient will proceed to inclusion and 
the randomisation procedure.
Inclusion
Patients are recruited for inclusion by their treating 
physicians at location. Following inclusion PRP will be 
prepared according to the PRP system instructions of the 
manufacturer. During the first two consultations, a total 
of two intra-articular injections will be documented with 
a time interval of 6 weeks. The patient will have no addi-
tional costs to usual care as a result of taking part in this 
study.
Physical examination will be performed on three occa-
sions up to 26 weeks from baseline. Patient-reported 
outcome measures (PROMs) will be used to evaluate the 
treatment effect up to 5 years. A cost-effectivity analysis 
will be performed at 1 year using the PROductivity and 
DISease Questionnaire (PRODISQ). The time-frame 
of the follow-up questionnaires is further illustrated in 
table 1. Questionnaires will be managed and distributed 
digitally using a GCP-approved data management system 
(Castor EDC).
replacement of individual patients after withdrawal
In the sample size calculation, we compensated for an 
expected loss of 10% of patients to follow-up. No patients 
will be replaced after withdrawal.
Safety
All adverse events reported spontaneously by the 
patient or observed by the investigator or his staff will 
be recorded. A variety of conditions have been treated 
with PRP ranging from muscle and tendon injuries to 
intra-articular injections of the knee and ankle. To date, 
no serious adverse events have been documented in the 
literature, concerning PRP intra-articular injections of 
the ankle. In accordance with the Central Committee on 
Research Involving Human Subjects guidelines, this study 
was classified as low risk for adverse events. Therefore, 
the local Medical Ethical Commission will be notified of 
any serious adverse events. In the event this happens, the 
advice of the Medical Ethical Commission will be followed 
accordingly.
outcome measures
Primary study parameter/end point
The primary objective of this study will be to quantify 
pain or functional improvement using the American 
Orthopaedic Foot and Ankle Society (AOFAS) score at 
26 weeks follow-up. Studies evaluating the efficacy of 
PRP in knee OA maintained a follow-up between 3 and 
12 months. We therefore opted to take 26 weeks for our 
primary outcome measure.10 The AOFAS is a validated 
scale for ankle OA (0–100) measuring three subdomains 
(pain, function and alignment), which together total 
nine items.20–23 The subdomain of pain is measured by 
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Table 1 Time-frame of the follow-up questionnaires
Follow-up
Baseline  ► First intervention injections
 ► Physical examination
 ► AOFAS
 ► PROMs
 ► PRODISQ cost-effectivity
6 weeks  ► Second intervention injection
 ► Physical examination
 ► AOFAS
 ► PROMs
12 weeks  ► AOFAS
 ► PROMs
 ► PRODISQ cost-effectivity
26 weeks  ► AOFAS
 ► PROMs
 ► PRODISQ cost-effectivity
39 weeks  ► PRODISQ cost-effectivity
52 weeks  ► AOFAS
 ► PROMs
 ► PRODISQ cost-effectivity
5 years  ► AOFAS
 ► PROMs
In addition to the AOFAS score, the following PROMs will be taken: 
FAOS, AOS, VAS, AAS, SF-36, GAS, EQ-5D-3L. These PROMs will 
be elaborated on further on. Furthermore, PRODISQ will be used 
to perform a cost-effectivity analysis. These questionnaires can be 
found in online supplementary appendix 1.
AAS, Ankle Activity Score; AOFAS, American Orthopaedic Foot 
and Ankle Society; AOS, Ankle Osteoarthritis Score; EQ-5D-3L, 
EuroQol-5 dimensions-3 levels; FAOS, Foot and Ankle Outcome 
Score; GAS, Global Attainment Scaling; PRODISQ, PROductivity 
and DISease Questionnaire; PROM, patient-reported outcome 
measures; SF-36, subjective patient satisfaction Short Form Health 
Survey-36; VAS, Visual Analogue Scale.
one item where a maximal score of 40 indicates no pain. 
Function consists of 7 items where full function is indi-
cated by the maximal score of 50 points. Similar to the 
pain subdomain, alignment has a potential maximum 
score of 10 points using one item, indicating good align-
ment.20 21 The AOFAS questionnaire, having undergone 
forward and backward translation to Dutch by de Boer 
et al, has an excellent internal consistency (Cronbach’s 
α=0.947) and an excellent test–retest reliability (Intra-
claas Correlation Coefficient 0.93).20
Secondary study parameters/end points
Secondary outcome measures are a number of other 
PROMs. Specific time points of the secondary outcome 
measures can be found in table 1.
1. Ankle Osteoarthritis Score (AOS) is a Visual Analogue 
Scale (VAS) from 0 to 100 mm with 18 questions; 9 re-
lating to pain and 9 relating to disability.
2. Foot and Ankle Outcome Score (FAOS): each ques-
tion is assigned 0–4 points based on the answer given. 
The scale runs from 0 (extreme symptoms) to 100 
points (no symptoms).
3. In order to evaluate pain, the pain subscale of AOFAS 
(0–40 points) will be analysed. On this scale, the lower 
the score the more pain the patient has. Additionally, 
a VAS score (VAS 0–100 mm) is measured during ac-
tivities of daily living, with 0 mm being no pain and 
100 mm the worst pain imaginable.
4. Total AOFAS score at the other time points than the 
primary one (at 6, 12 and 52 weeks as well as 5 years).
5. Ankle Activity Score (0–10 points) is scored accord-
ing to chart based on the performable activity level
6. Subjective patient satisfaction (four categories): poor, 
fair, good, excellent.
7. Short Form Health Survey-36 is a health-related quali-
ty of life score (0–100 points). The higher the patient 
scores, the higher the disability.
8. The Global Attainment Scaling is a method of scor-
ing based on achievement related to predetermined 
goals in agreement with the patient. Points are sub-
tracted for not achieving the predefined goals or vice 
versa. Scores range from 100 (high functioning) to 0 
(severely impaired)
9. EuroQol-5 dimensions-3 levels (EQ-5D-3L) utili-
ty score allows a patient’s health to be defined by a 
5-digit number.
10. PRODISQ will be used to determine indirect costs 
and direct costs cost-effectivity. PRODISQ is taken at 
baseline and every 3 months thereafter up until 1 year. 
This will be done in conjunction with the EQ-5D-3L.
loss to follow-up
The coordinating researcher will attempt to limit loss to 
follow-up as much as possible by contacting every patient 
and being present at every patient visit. All digital ques-
tionnaires will be constantly monitored to ensure they are 
being filled in and otherwise followed up by the coordi-
nating researcher. In the event of patient withdrawal, an 
analysis of demographic and prognostic characteristics 
will be done on these cases and the remaining patients. 
As previously described by Järvinen et al, we will docu-
ment the patient eligible for and compliant with each 
follow-up.24
Missing items
Missing items of a score will be handled according to 
the instructions of the specific scales. In the event of no 
instructions, we will calculate the percentage of missing 
items on a scale. Due to the potential impact on trial 
conclusions, multiple imputation (if >10% missing items 
on a scale) will be applied.
Sample size
Based on previous and ongoing studies, the study 
protocol of the RCT is designed to detect a difference of 
12 points (0–100) on the AOFAS score. There is no offi-
cial agreement on the minimal clinical important differ-
ence for the AOFAS score regarding ankle OA. However 
in relatable musculoskeletal literature, 10%–15% of the 
used scale was reported.13 25 26 Our predefined minimal 
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clinical important difference of 12% is located within this 
range.13 25 26 Based on a previous placebo-controlled RCT 
on injection therapy (hyaluronic acid) in ankle OA by De 
Groot et al, an SD of 16.3 can be expected.6 Taking into 
account a two-sided level of significance of 5%, a power 
of 90% and a dropout rate of 10%, approximately 50 (45 
plus 10% drop out) patients per group will be needed 
(n=100 in total).
data management
After giving permission for participating in this study, 
patients will receive a link to fill in digital surveys. All data 
gained outside Castor EDC will be stored on the AMC 
secured hard drive. All data will be coded and stored in 
the Castor EDC online database, which meets the AMC 
safety criteria and GCP guidelines. The primary investi-
gator and project leader will safeguard the coded data 
through password secured access. All patient’s data will 
be archived for at least 15 years and handled with in 
accordance with the Dutch Personal Data Protection Act 
(Wbp). Data protection is provided through the safety 
protocol of Castor EDC with automated backups and 
Secure Sockets Layer (SSL) security.
Statistical analysis
A standard operating procedure will be available to logi-
cally recode and clean the data. The data will be inter-
preted according to a blinded data interpretation scheme 
described by Järvinen et al.24 A statistical expert (SB) is 
present among the authors. The authors will interpret 
the statistical results until a consensus is reached. Once 
the authors are in agreement, the two groups will be 
unblinded and no changes will be made to the interpre-
tation of the results.
baseline characteristics
Baseline characteristics will be analysed between groups 
using descriptive statistics.
Primary outcome measure
Analysis will be performed using an intention-to-treat 
approach. To test for the effect of treatment on the 
between-group difference in primary outcome, we will use 
a repeated measurement general linear model. Changes 
from baseline to all follow-up time points will be included 
in the model. Adjustments will be made for those base-
line variables that influenced the primary outcome with 
p<0.10.
Secondary outcome measures
To test for the effect of treatment on between-group 
differences in secondary outcomes, we will use the 
repeated measurement general linear model. Changes 
from baseline to all follow-up time points will be included 
in the model.
Economic analysis
In the event of a positive significant outcome, an economic 
analysis is needed to support a possible change of practice. 
An economic analysis (costs) will be performed in order 
to determine cost-effectiveness.
We will assess the differences in mean quality-adjusted 
life years (QALYs), costs and net benefits between the 
PRP injection group and the placebo group using linear 
models. We express the cost-effectiveness by using cost-ef-
fectiveness acceptability curves from both a healthcare 
perspective and a societal perspective. With multiple 
bootstrap replicates of the average difference in costs and 
effects in the incremental cost-effectiveness plane, we will 
express the uncertainty of our cost-effectiveness analysis.
The cost-effectivity analysis will be performed with a 1 
year time horizon. We use the three-level EQ-5D ques-
tionnaire (Euroqol, Rotterdam, the Netherlands) to 
calculate QALYs as the area under the curve of the utility 
scores measured over 12 months, according to the Dutch 
pricing system. The analysis will be based on indirect costs 
and direct costs and will be determined using PRODISQ. 
PRODISQ is taken at baseline and every 3 months there-
after up until 1 year.
Monitoring committee
The PRIMA trial will be monitored by the clinical research 
unit (CRU) of the coordination study centre. The CRU 
aims to improve the quality of clinical research and ulti-
mately, patient care. Before the PRIMA trial commenced, 
a monitoring plan was set-up. This monitoring plan facil-
itates compliance with the Human Research Act (WMO), 
GCP (ICH-GCP) guidelines (5.18.1) and/ or ISO14155, 
which require monitors to verify that:
1. the rights and well-being of human subjects are 
protected;
2. recorded study data are accurate, complete and verifi-
able with the source documents;
3. the conduct of the study is compliant with the cur-
rently approved protocol and with applicable laws reg-
ulatory requirements, for example, WMO, ICH-GCP, 
ISO14155.
Throughout the study, monitoring will be performed 
at initiation of the trial, at each participating centre once 
approximately three patients have been enrolled, after 
approximately 10–15 enrolled patients have completed 
the 26-week follow-up, after 70 patients have been 
enrolled and after database lock.
Ethics and dissemination
In the events of amendments or other changes, co-re-
searchers will be notified. If relevant, patients partici-
pating will also be notified. Intellectual data will be the 
property of the PRIMA study group. Participant data that 
underline the results reported in this article following 
de-identification will be shared anonymously on request 
following publication. Data will be shared, wherever 
legally and ethically possible and in line with ICMJE 
guidelines, with researchers who provide a methodolog-
ically sound proposal. Data will be stored in a repository 
(Figshare) under management of the medical library of 
the AMC. Any proposal should contain: title, background, 
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rationale, objective, methods (eligibility criteria, variables 
and timeframe of interest, statistical plan), information 
regarding publication including authorship.
The results of this project study and new knowledge 
will be disseminated through the Dutch Arthritis Asso-
ciation (ReumaNederland), presentations, news publi-
cations, blogs, websites, social media and professional 
organisations (rheumatology, orthopaedics, primary care 
medicine, sports medicine, public health) and the Dutch 
patient federation (Patiëntenfederatie Nederland). 
The patients will also be informed about the results of 
the study. The study will be conducted according to the 
principles of the Declaration of Helsinki, GCP and the 
Medical Research Involving Human Subjects Act (WMO). 
The board of each participating hospital reviewed and 
approved the local feasibility. Monitoring and auditing 
will be carried out throughout the study. In the event 
of serious adverse events, these will be documented and 
reported to the monitor and the Medical Ethics board. 
Eligible patients will be informed of the study and will 
sign an informed consent form before participating 
(acquired by researchers associated with the study). Provi-
sions for post-trial care as compensation for those who 
suffer harm from trial participation is documented in the 
patient information.
dISCuSSIon
This is the first study evaluating the efficacy and cost-ef-
fectiveness of PRP injections in the treatment of ankle OA 
with a multicentre, stratified, block-randomised, double-
blind, placebo-controlled design. The primary outcome is 
the AOFAS score at 26 weeks. Our study will also evaluate 
the long-term efficacy of PRP for up to 5 years.
PRP has been shown to alleviate symptoms of patients 
suffering from knee OA.11 In the absence of effective 
evidence-based non-surgical interventions for ankle OA, 
PRP would fulfil a clear clinical need. Previous trials 
concerned with the efficacy of PRP for multiple indica-
tions are usually of low quality and adhere to a follow-up 
of 26 weeks or shorter. Furthermore, a cost-effectiveness 
analysis has never been performed in previous trials on 
PRP in the treatment of OA.
A positive study outcome would have a significant 
impact leading to change in clinical practice, where PRP 
could be offered as a non-surgical intervention. A nega-
tive outcome will prevent the widespread use of a non-ef-
ficacious treatment.
This study has potential limitations. First of all, due to 
financial constraints (semi-quantitative), MRI-defined 
cartilage degenerative changes will not be used as a 
secondary outcome score. Furthermore, the composition 
of PRP is not analysed. This decision is based on the fact 
that PRP preparation and composition has frequently 
been analysed and is typically not performed in clinical 
practice prior to injection.27 The PRP we use (Hettich 
Rotofix32 A centrifuge and Arthrex syringes) is one out 
of a multitude of commercially available PRP products. 
All these products differ in their production method and 
content, and different treatment regimens regarding 
dose, timing and number of injections are used in clinical 
practice. The generalisability to other PRP products and 
treatment regimens remains unknown.
ConCluSIon
This will be the first RCT to assess the efficacy and cost-ef-
fectiveness of PRP in ankle OA.
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